We will make headway into the global market beyond the domestic market by gathering the ability of JW.
-First domestic partnership with Tempus AI, the world’s largest holder of clinical and genomic...
-Integration of existing AI drug development platforms ‘Jewelry’ and ‘Clover’ with expan...
Leveraging Zebrafish with 80–90% genetic similarity to humans to expand new drug pipelinesColl...
-Lead compound selectively and directly inhibits XBP1s-Supported by research funding for two y...
-STAT3 Inhibitor JW2286 Developed as a First-in-Class Global Innovative Drug-Expected to Addre...
-First Efficacy Evaluation on Human Skin Organoids and Androgenic Alopecia Animal Model Reveal...
-Discovered through the new drug development platform ‘JWELRY,’ targeting the Wnt signaling pa...
-DSMB's primary evaluation based on safety data from gout patients is positive-Accelerating Ph...
-Phase 3 IND approvals completed in 5 Asian countries, including Korea... Efficacy in reducing...
-Optimization of Lead Compounds for Direct STAT6 Inhibition-Utilization of XtalPi’s AI Drug De...